As it investigates a promising candidate to treat metabolic dysfunction-associated steatohepatitis (MASH), 89bio is laying the bricks to manufacture and commercialize the potential treatment. Now, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback